California has made a great commitment to produce its own insulin, but there is still no “safe date” for delivery

Read this story in English

Two years ago, California made a bold message: it will produce low insulin and state brand. Medicine manufacturers, insurers, economists and diabetics have taken into account. He had the potential to change the market, reduce the cost of drugs and save lives from patients.

Governor Gavin Newsom He promised “Delivery in 2024” of insulin.

This time has not yet arrived and the American Diabetes Association says that the delay harms diabetics that need a low cost for the medicine.

“We were late by one year more than a year and we do not see the end of sight,” says Christine Falabel, regional director of government affairs at the Association, during a recent recent Supervisory Concerning the Senate initiative.

During the hearing, the representatives of the Newsom Administration said they could not provide a schedule when the state insulin would be on sale. Falabel said Californians could wait until 2030

More than 3.5 million Californians have diabetes, and insulin is a vital part of the management and treatment of their disease.

Civica, Inc., Non -Profit Drug Producer Hired to develop five types of insulin for the state has not yet initiated clinical trial Calmatters reports Last month.

The American Diabetes Association expects more delays in the insulin project known as CALRX, given the duration of clinical trials and unforeseen challenges characteristic of the regulatory process. Several drug production experts have told Calmatters that the process of examination of FDA drugs is “if nothing goes wrong.” A clinical trial can also add another year or more.

“Based on the condition that Calrx presented (during the public), we expect a significant delay in the schedule for when insulin will be available through the program,” Falabel told Calmatters.

Civica did not participate in the audience, but had previously told Calmatters that the company had started producing insulin, which is one of the steps to be implemented before they submit the application for FDA approval.

“We want to be careful about the expectations we generate,” said Alan Kukel, a civil government director. “It is not uncommon for things to happen in a complex program and you need to adapt.”

During the hearing of the supervision, Elizabeth Landsberg, Director of the State Department of Access and Information on Health and Information, said the rhythm of the development of insulin Calrx was more slow than the state was expected but “not outside the industrial standards”. The Landsberg Division is tasked with leading the insulin initiative.

“I would like to be able to sit here today and say we have a safe meeting,” Lansberg said.

NEWSOM declined to limit insulin costs

NEWSOM introduced the $ 100 million insulin initiative as a radical way to change the pharmaceutical market, where the price of insulin almost tripled between 2012 and 2021, according to The The Institute of Medical ExpenditureS The goal was to increase competition in an area where three manufacturers – Eli Lily, Nova Nordis and Sanofi – have been controlling the market for decades.

Half of the state money will be allocated to Civica, Inc. to produce fast and prolonged insulins for California at their Virginia plant. The other half will be used to help open a production plant in California. Insulin will be sold at $ 30 on a $ 10 milliliters or $ 55 per box of five feathers of 3 milliliters.

Last analyzes indicate that Medium pocket costs for insulin delivery per month This is $ 58, although some people pay much more than that, especially if they do not have medical insurance. Some manufacturers also have an independent limited cost of up to $ 35 per month.

Landsberg said there was no update to the production plant during the audience.

At the same time, Newsom has veto accounts that would have Limited pocket costs in insulin y Regulated to administrators of pharmaceutical benefitsMediators between drug manufacturers and insurers who determine which medicines are covered for beneficiaries. Evidence indicates that these benefits administrators are Partially responsible for elevated drug pricesS

In veto reports to this bill, Newsom pointed to Calrx as part of its reasoning to reject medical care measures.

“I think sometimes the message is transmitted that Calrx is the full solution for everything related to the price of medical care,” said Senator Scott Wiener, president of the Senate Budget Committee during the audience. “This is not the case at all.”

Wiener, Democrat from San Francisco, has been the author of the latest attempts to limit patients’ insulin patients to $ 35 a month and regulates pharmaceutical benefits administrators, and they both approved almost unanimously, but vetoed the governor.

Wiener said he supported the Calrx program, but it was not “the only solution to reduce medication costs.” He returned to the current versions of the two bills.

Insulin producers smaller prices

California’s efforts to make insulin more accessible were abandoned by those of other states and the federal government.

Last year, Eli Lily, Novo Nordisk and Sanofi reduced insulin prices between 65% and 80%. Sector experts attribute the fall in a change in Medicaid standards that associate the prices of inflation drugs, which means that pharmaceutical companies would have hundreds of millions of dollars due to the high prices of insulin due to the federal government.

But these price reductions did not help everyone, Falabel said. The design of the insurance benefits of each individual, as well as high deductions, means that many people still cannot pay their insulin. In a recent study, the association found that approximately 16% of adults using insulin ration Due to the price.

The American Diabetes Association is advocating for California to introduce a restriction on the price of the insulin pocket in addition to filling in the Calrx program.

Twenty -five states and Colombia County have applied monthly insulin prices, and some Medicare users have a limited cost of up to $ 35 per month.

This note is made with the support of the California Foundation for Health (CHCF), which works to ensure that people have access to the right attention when they already need a price they can pay. Visit www.chcf.org for more information.

This article was originally published by CalmattersS